↓ Skip to main content

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study

Overview of attention for article published in BMC Cancer, August 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

twitter
8 X users

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
71 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study
Published in
BMC Cancer, August 2016
DOI 10.1186/s12885-016-2692-4
Pubmed ID
Authors

Trinidad Dierssen-Sotos, Inés Gómez-Acebo, María de Pedro, Beatriz Pérez-Gómez, Sonia Servitja, Víctor Moreno, Pilar Amiano, Tania Fernandez-Villa, Aurelio Barricarte, Adonina Tardon, Marian Diaz-Santos, Rosana Peiro-Perez, Rafael Marcos-Gragera, Virginia Lope, Esther Gracia-Lavedan, M. Henar Alonso, Maria Jesus Michelena-Echeveste, Andrés Garcia-Palomo, Marcela Guevara, Gemma Castaño-Vinyals, Nuria Aragonés, Manolis Kogevinas, Marina Pollán, Javier Llorca

Abstract

The relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or presence of hormonal receptors). In this case-control study, we report the NSAID - breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women's characteristics (i.e.: menopausal status or body mass index category) and by tumor characteristics. In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76; 95 % Confidence Interval [CI]: 0.64-0.89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in advanced clinical stage and triple negative cancers. Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 71 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 9 13%
Student > Ph. D. Student 7 10%
Researcher 7 10%
Student > Bachelor 7 10%
Other 6 8%
Other 14 20%
Unknown 21 30%
Readers by discipline Count As %
Medicine and Dentistry 16 23%
Unspecified 9 13%
Pharmacology, Toxicology and Pharmaceutical Science 5 7%
Biochemistry, Genetics and Molecular Biology 3 4%
Chemistry 3 4%
Other 7 10%
Unknown 28 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 September 2016.
All research outputs
#6,229,018
of 22,883,326 outputs
Outputs from BMC Cancer
#1,558
of 8,326 outputs
Outputs of similar age
#99,218
of 343,760 outputs
Outputs of similar age from BMC Cancer
#37
of 279 outputs
Altmetric has tracked 22,883,326 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 8,326 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,760 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 279 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.